Clene (CLNN) News Today $4.79 -0.10 (-2.04%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period IBN Coverage: Clene (NASDAQ: CLNN) Paves Cash Runway to Advance CNM-Au8(R) for ALSJanuary 13, 2025 | finance.yahoo.comEmisphere Technologies (OTCMKTS:EMIS) & Clene (NASDAQ:CLNN) Head-To-Head SurveyJanuary 10, 2025 | americanbankingnews.comIBN Coverage: Clene (NASDAQ: CLNN) Receives FDA Roadmap on Potential Accelerated Pathway for CNM-Au8(R)December 30, 2024 | finance.yahoo.comClene (NASDAQ: CLNN) Receives FDA Roadmap on Potential Accelerated Pathway for CNM-Au8(R)December 27, 2024 | theglobeandmail.comIBN Coverage: Clene (NASDAQ: CLNN) Secures $10M Debt Facility to Advance Neurodegenerative Disease TreatmentsDecember 21, 2024 | finance.yahoo.comClene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing Senior LoanDecember 19, 2024 | markets.businessinsider.comClene (NASDAQ: CLNN) Secures $10M Debt Facility to Advance Neurodegenerative Disease TreatmentsDecember 19, 2024 | theglobeandmail.comPromising Prospects for Clene’s ALS Treatment: Buy Recommendation Backed by Robust Data and Regulatory ProgressDecember 12, 2024 | markets.businessinsider.comIBN Coverage: Clene (NASDAQ: CLNN) Advances CNM-Au8 in ALS With FDA Guidance on Accelerated Approval PathwayDecember 12, 2024 | finance.yahoo.comClene Inc. Receives FDA Guidance on Accelerated Approval Pathway for CNM-Au8® in ALS, Plans NDA Submission for Mid-2025December 10, 2024 | quiverquant.comFDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALSDecember 10, 2024 | globenewswire.comClene price target lowered to $84 from $90 at BenchmarkNovember 22, 2024 | markets.businessinsider.comClene price target lowered to $83 from $86 at CanaccordNovember 14, 2024 | markets.businessinsider.comClene’s Strategic and Financial Strengths Justify Buy Rating Amid Promising ALS Therapeutic DevelopmentsNovember 14, 2024 | markets.businessinsider.comClene Reports Third Quarter 2024 Financial Results and Recent Operating HighlightsNovember 13, 2024 | markets.businessinsider.comClene Reports Third Quarter 2024 Financial Results and Recent Operating HighlightsNovember 13, 2024 | markets.businessinsider.comClene Announces Q3 2024 Results and ALS Drug ProgressNovember 13, 2024 | markets.businessinsider.comClene Announces Q3 2024 Results and ALS Drug ProgressNovember 13, 2024 | markets.businessinsider.comIBN Coverage: Clene (NASDAQ: CLNN) Set to Discuss Lead Candidate Biomarker With FDA LeadershipOctober 25, 2024 | finance.yahoo.comClene (NASDAQ: CLNN) Set to Discuss Lead Candidate Biomarker with FDA LeadershipOctober 25, 2024 | theglobeandmail.comIBN Coverage: Clene (NASDAQ: CLNN) Presents Lead Candidate CNM-Au8(R) Updates at Investor ConferencesOctober 21, 2024 | finance.yahoo.comIBN Coverage: Clene (NASDAQ: CLNN) Closes $7.3M Registered Direct Offering and Concurrent Private PlacementsOctober 11, 2024 | finance.yahoo.comClene to Present at Upcoming October ConferencesOctober 9, 2024 | finance.yahoo.comIndependent Chairman of the Board of Clene David Matlin Buys 26% More SharesOctober 6, 2024 | finance.yahoo.comClene Inc. chief science officer purchases $97,432 in company stockOctober 3, 2024 | investing.comClene (NASDAQ: CLNN) Closes on Direct Offering, Concurrent Private Placements Totaling $7.3MOctober 3, 2024 | theglobeandmail.comIBN Coverage: Clene (NASDAQ: CLNN) Closes on Direct Offering, Concurrent Private Placements Totaling $7.3MOctober 3, 2024 | finance.yahoo.comClene Inc. (NASDAQ:CLNN) Director David J. Matlin Buys 92,307 SharesOctober 3, 2024 | insidertrades.comIBN Coverage: Clene (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private PlacementsOctober 2, 2024 | finance.yahoo.comMark Mortenson Buys 20,512 Shares of Clene Inc. (NASDAQ:CLNN) StockOctober 2, 2024 | insidertrades.comClene (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private PlacementsOctober 2, 2024 | theglobeandmail.comClene Announces Closing of $7.3 Million Registered Direct Offering and Concurrent Private Placements and Amendment of Debt FacilityOctober 2, 2024 | stockhouse.comClene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq RulesSeptember 30, 2024 | globenewswire.comIBN Coverage: Clene (NASDAQ: CLNN) to Discuss CNM-Au8(R) Data FDA LeadershipSeptember 26, 2024 | finance.yahoo.comClene’s CNM-Au8 Shows Promise in ALS Treatment Despite Trial Setbacks: A Strong Buy RecommendationSeptember 19, 2024 | markets.businessinsider.comBuy Rating Justified by Regulatory Progress and Positive ALS Treatment Data for Clene’s CNM-Au8September 18, 2024 | markets.businessinsider.comClene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival DataSeptember 16, 2024 | globenewswire.comEF Hutton Initiates Coverage of Clene (CLNN) with Buy RecommendationSeptember 11, 2024 | msn.comClene (NASDAQ: CLNN) Management to Present at H.C. Wainwright Investment ConferenceSeptember 5, 2024 | theglobeandmail.comClene (NASDAQ: CLNN) Positioned as Leader in Addressing Neurodegenerative DiseasesSeptember 5, 2024 | theglobeandmail.comIBN Coverage: Clene (NASDAQ: CLNN) Management to Present at H.C. Wainwright Investment ConferenceSeptember 4, 2024 | finance.yahoo.comIBN Coverage: Clene (NASDAQ: CLNN) Positioned as Leader in Addressing Neurodegenerative DiseasesSeptember 3, 2024 | finance.yahoo.comBioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Management to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | msn.comClene to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | globenewswire.comIBN Coverage: Clene (NASDAQ: CLNN) CEO Discusses CNM-Au8(R) Trial Results on BioMedWire PodcastAugust 30, 2024 | finance.yahoo.comBioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Positioned as Leader in Addressing Neurodegenerative DiseasesAugust 30, 2024 | msn.comClene’s (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers, Long-term Survival in ALS TrialsAugust 24, 2024 | theglobeandmail.comIBN Coverage: Clene's (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers, Long-term Survival in ALS TrialsAugust 24, 2024 | finance.yahoo.comClene (NASDAQ: CLNN) Makes Strides in Developing CNM-Au8(R) to Address Neurodegenerative ConditionsAugust 13, 2024 | theglobeandmail.comIBN Coverage: Clene (NASDAQ: CLNN) Makes Strides in Developing CNM-Au8(R) to Address Neurodegenerative ConditionsAugust 13, 2024 | finance.yahoo.com Get Clene News Delivered to You Automatically Sign up to receive the latest news and ratings for CLNN and its competitors with MarketBeat's FREE daily newsletter. Email Address CLNN Media Mentions By Week CLNN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLNN News Sentiment▼0.630.57▲Average Medical News Sentiment CLNN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLNN Articles This Week▼12▲CLNN Articles Average Week Get Clene News Delivered to You Automatically Sign up to receive the latest news and ratings for CLNN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ADCT News Today CHRS News Today GLSI News Today VXRT News Today DRUG News Today NKTX News Today PLX News Today ACTU News Today FATE News Today PBYI News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLNN) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
